Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.
about
Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infectionsEffects of sulfamethizole and amdinocillin against Escherichia coli strains (with various susceptibilities) in an ascending urinary tract infection mouse modelIn vivo pharmacodynamic characterization of a novel plectasin antibiotic, NZ2114, in a murine infection modelBTS Guidelines for the Management of Community Acquired Pneumonia in AdultsApplication of PK/PD Modeling in Veterinary Field: Dose Optimization and Drug Resistance PredictionAssociation between the AUC0-24/MIC Ratio of Vancomycin and Its Clinical Effectiveness: A Systematic Review and Meta-AnalysisModels of Respiratory Infections: Virus-Induced Asthma Exacerbations and BeyondImportance of relating efficacy measures to unbound drug concentrations for anti-infective agentsAlternative strategies for proof-of-principle studies of antibacterial agentsDose optimisation of antibiotics in children: application of pharmacokinetics/pharmacodynamics in paediatricsOptimizing antimicrobial therapy in critically ill patientsAntiretroviral pharmacology in mucosal tissuesImplementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical ResearchPharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient PopulationsTherapeutic drug monitoring of the β-lactam antibiotics: what is the evidence and which patients should we be using it for?Beyond Susceptible and Resistant, Part II: Treatment of Infections Due to Gram-Negative Organisms Producing Extended-Spectrum β-LactamasesDifferences between ceftriaxone and cefotaxime: microbiological inconsistenciesCarbapenemsThe pharmacokinetics and pharmacodynamics of the carbapanemes: focus on doripenemClinical review: balancing the therapeutic, safety, and economic issues underlying effective antipseudomonal carbapenem useCorrelation between in vitro and in vivo activities of GM 237354, a new sordarin derivative, against Candida albicans in an in vitro pharmacokinetic-pharmacodynamic model and influence of protein bindingIntravitreal vancomycin and gentamicin concentrations in patients with postoperative endophthalmitisHigh protein binding and cidal activity against penicillin-resistant S. pneumoniae: a cefditoren in vitro pharmacodynamic simulationDetermination of therapeutic equivalence of generic products of gentamicin in the neutropenic mouse thigh infection modelOptimal drug synergy in antimicrobial treatments"One-size-fits-all"? Optimizing treatment duration for bacterial infectionsTwo-drug antimicrobial chemotherapy: a mathematical model and experiments with Mycobacterium marinumCiprofloxacin modulates cytokine/chemokine profile in serum, improves bone marrow repopulation, and limits apoptosis and autophagy in ileum after whole body ionizing irradiation combined with skin-wound traumaPharmacokinetics-pharmacodynamics analysis of bicyclic 4-nitroimidazole analogs in a murine model of tuberculosisBacterial temporal dynamics enable optimal design of antibiotic treatmentDistinguishing Antimicrobial Models with Different Resistance Mechanisms via Population Pharmacodynamic ModelingClinical Validation of Therapeutic Drug Monitoring of Imipenem in Spent Effluent in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Pilot StudyIn Vivo Pharmacokinetics/Pharmacodynamics of Cefquinome in an Experimental Mouse Model of Staphylococcus Aureus Mastitis following Intramammary InfusionPreclinical Evaluation of the Stability, Safety, and Efficacy of CD101, a Novel EchinocandinPharmacotherapy during pediatric extracorporeal membrane oxygenation: a review.Pharmacokinetics of ceftriaxone in plasma and bone of patients undergoing hip or knee surgery.Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics.Chairman's introduction--the importance of good quality surveillance data today.The role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data.Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint
P2860
Q24199096-94655A37-7005-4586-923D-749FA11B0EAAQ24550534-6E31F7D9-40BD-4A42-A7B7-283C9CF3845BQ24654780-8E129D3B-443C-447E-AF7F-A3FAF53EB881Q24675547-3E0A1AD6-27D8-4DAE-9CB8-BAADC275FE2EQ26753831-CC463996-FE19-4788-BCC0-50F2161AA012Q26770913-D9C617B1-6CD0-425E-B946-9010624DAC1EQ26786359-5800652E-437D-40C9-A7E0-A09C27D4A1A1Q26827380-D531AF55-1CC7-45B9-BE58-DD9EF53615F9Q26850895-D9483799-414C-4B17-BD27-200674B01C2BQ26853629-F603803E-928D-4C40-8F06-B0BDC4FDA559Q26999905-B59E127D-33FB-4B88-8CB4-961E929421D7Q27014675-A2B6E39C-DE3A-4532-9291-D9D0783E8C90Q27024682-06FE1265-0EE0-45C1-9FB9-D680C820EDF6Q28066877-8B181764-193E-4BEF-B442-EB6666BA2B06Q28080607-FB0A6D4E-5FB8-40E9-A4FF-0804D54E7A2EQ28249617-57D9ADD2-7352-431A-A103-626CA5383026Q28261698-0366C47D-D1B6-4A8C-B320-8DA19C46EA95Q28286055-2FEE58A0-4057-4B6B-9A6A-1B8106E864BFQ28289744-E7096565-BE96-400A-BF6A-922732F5A840Q28299749-56B56937-1844-4BE9-B00C-EE8D1E2A80C5Q28353204-1185DA32-55E9-429B-9FC7-74E672E43637Q28362428-9D31B154-9A68-4B39-B18B-310A575DEB31Q28473173-1890DEB1-D79F-4870-BE70-A080EC3866D1Q28474000-FCED8741-4818-4380-8C48-F96CB2B2B5ABQ28474170-5F6AAC8C-86C1-429E-A95B-50C77E70E173Q28478851-9C8B4D51-87DC-4318-AFBA-85B0B189C585Q28478890-B7261B60-593A-45F4-879C-FD06973C8EBDQ28487821-095C1101-158D-44E3-A320-2C229DCED483Q28542435-6CDF0ABC-4236-4371-91B2-C824FA10E574Q28546654-F5AC26EB-20F3-43E8-824B-47DDFCC1BA10Q28550711-9FF10B3C-039A-4447-9F73-23E6431D16B6Q28551453-A019A7A1-BC8A-4A8E-B1A5-B96D46C3249AQ28552364-41F1F857-2FBF-4AB9-9C45-20C1734D4913Q28821330-0BA96480-662C-4C35-94E0-62689A4021C6Q30249512-1E1830E9-F0CF-41CD-9E69-235015DB50EAQ30317265-EA50ECDF-5525-4574-9689-9EBFB5C6D24AQ30403958-C3F275E5-C6DC-4A8C-9DB3-E2C25F7B832FQ30573318-37748DC2-DC05-4A22-B2C4-335692F3F5BDQ30577239-FEE22904-B2DC-4963-ADDE-74E4695CAFC3Q30620954-2C509AAE-3DAC-4EF4-A58A-96369C90878E
P2860
Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Pharmacokinetic/pharmacodynami ...... terial dosing of mice and men.
@en
type
label
Pharmacokinetic/pharmacodynami ...... terial dosing of mice and men.
@en
prefLabel
Pharmacokinetic/pharmacodynami ...... terial dosing of mice and men.
@en
P356
P1476
Pharmacokinetic/pharmacodynami ...... terial dosing of mice and men.
@en
P2093
P304
1-10; quiz 11-2
P356
10.1086/516284
P407
P577
1998-01-01T00:00:00Z